Morgen is a time management platform that simplifies the scheduling process by integrating multiple calendars and task management tools into a single application. As the complexity of time management increases, Morgen addresses this challenge by offering a holistic solution that allows users to plan, organize, and optimize their schedules effectively. The platform combines various calendar systems and communication channels, enabling users to manage all events, tasks, lists, and reminders in one place. With its native scheduling tool, Morgen helps individuals and teams reduce meeting chaos and streamline their daily activities, making time management more efficient and less fragmented.
turicode Inc. develops software as a service (SaaS) platform for document processing. Its software reads and understands documents such as PDFs, scans, and emails. The company’s MINT.extract platform helps companies and their employees to digitize document. It serves legal and tax, financial industry, healthcare, logistics, insurance, and archives industries. turicode Inc. was founded in 2016 and is based in Winterthur, Switzerland.
Ledgy AG, a technology company, operates Software-as-a-Service platform to manage and exchange securities in private companies. Its platform is used for shares management for companies and shareholders. The company was founded in 2017 and is based in Zurich, Switzerland.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
MESA Imaging is focusing on the development and production of 3D time-of-flight cameras.
Ledgy AG, a technology company, operates Software-as-a-Service platform to manage and exchange securities in private companies. Its platform is used for shares management for companies and shareholders. The company was founded in 2017 and is based in Zurich, Switzerland.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Advanon AG, based in Zurich, Switzerland, operates an online financial services platform that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015, the platform allows businesses to pre-finance their invoices, enabling them to access liquidity without the long wait times typically associated with customer payments, which can range from 30 to 120 days. This service provides SMEs with flexible financing options that help strengthen their cash flow and support growth. Advanon is recognized as a financial intermediary and complies with regulatory standards set by the Swiss Financial Market Supervisory Authority (FINMA) under the Anti Money Laundering Act.
Inositec AG is a biotechnology company based in Zurich, Switzerland, established in 2015 as a spin-off from ETH Zurich. The company specializes in the development of drug therapies derived from its proprietary Inositune platform, which utilizes inositol phosphate analogs with adjustable properties. Inositec's lead product, INS-5010, is a non-antibiotic therapy designed to target colon infections caused by Clostridium difficile. Additionally, the company addresses soft tissue calcification disorders, focusing on vascular and renal calcification, including orphan indications. By selectively modifying the phosphate groups in inositol phosphate compounds, Inositec aims to create molecules with improved drug-like properties tailored for specific therapeutic applications.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Sonic Emotion AG, founded in 2002 and headquartered in Zurich, Switzerland, specializes in advanced audio solutions that create immersive sound experiences. The company's flagship technology, Sonic Emotion Absolute 3D, enables natural 3D sound reproduction using sound field control from as few as two channels, allowing for compact audio setups suitable for a variety of environments. Sonic Emotion AG caters to diverse markets, providing audio solutions for 3D cinemas, events, trade fairs, museums, theme parks, and dance shows. Additionally, the company offers audio simulation services, OEM licensing solutions, and a sound enhancement application named Headquake for Apple i-device products. With research facilities in France and sales offices across Asia, including China, Hong Kong, Taiwan, and Japan, Sonic Emotion AG is positioned to deliver cutting-edge audio technology globally.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Visonys
Venture Round in 2006
Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.
Avalon Photonics
Venture Round in 2003
Avalon Photonics produces world-class VCSELs (vertical cavity surface emitting lasers) for datacom, sensing, and measurement markets. These devices are enabling volume applications due to their exceptional performance, lower power consumption, and volume cost reduction.Avalon also produces unique, patent-protected, single-spatial-mode VCSELs with unsurpassed specifications required for many sensing and measurement applications. Avalon’s ISO 9001 production line achieves high quality, exceptional uniformity, and telecom-grade reliability devices. VCSELs can be provided from bare die up to fully packaged units with temperature control and fiber pigtailing.